Morgan Stanley Raises Danaher (DHR) Price Target to $240
Morgan Stanley has reiterated its Overweight rating on Danaher Corporation with a new price target of $240, a 4.60% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Morgan Stanley raised its price target on Danaher Corporation ($DHR) to $240 from $220 on October 13, 2026, and rates the stock "Overweight".
Since the rating, $DHR is up 2.8% to date (from the $222.84 close on Oct 13, 2026).
DHR
Danaher Corporation
Key Points
- On October 13, 2026, Morgan Stanley reiterated its Overweight rating on Danaher Corporation, setting a price target of $240, up from $220.
- Morgan Stanley's $240 price target implies 4.60% upside from Danaher Corporation's ($DHR) current $229.45 share price.
- The stock is currently trading at $229.45, which is about 4.4% below the new analyst target.
- Danaher has a market cap of approximately $162.7 billion and a P/E ratio of about 41.3.
Get $DHR trade alerts by text
We text you when insiders, Congress or big funds trade $DHR. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Danaher Corporation alert may contain errors. Disclosures
Morgan Stanley has reiterated its Overweight rating on Danaher Corporation (NYSE: DHR) on October 13, 2026, raising its price target from $220 to $240. This move comes as the stock trades at around $229.45 as of October 16, 2026.
Other Institutional Activity in Danaher Corporation
Several other institutional investors have updated their positions in Danaher recently. Blackrock Inc. grew its holdings by 3,444,403 shares, bringing its total to about 55,084,630 shares worth approximately $12.6 billion. FMR, LLC increased its stake by 7,006,075 shares, resulting in a total of 29,540,895 shares valued at about $6.8 billion. Wellington Management Group, LLP added 1,542,446 shares, ending with 16,316,834 shares worth about $3.7 billion.
Danaher Corporation Stock Up 2.1%
As of October 16, 2026, Danaher shares are trading at $229.45, which is above its 50-day moving average of $213.32 by 7.6% and above its 200-day moving average of $201.33 by 14.0%. However, the stock is about 5.5% below its 52-week high of $242.80, indicating some room for growth.
$DHR price target
Danaher Corporation daily closes and this analyst's $240 target. Not advice.
Recent Earnings
Danaher reported trailing twelve-month revenue of approximately $25.1 billion, showing a year-over-year revenue growth of 5.5%. The company has a net margin of 15.9% and a return on equity of 7.6%. Its next earnings report is scheduled for October 21, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
5 target cuts vs 1 raises.
-
EPS & revenue
EPS beat estimates by 5.3%. Revenue missed estimates by 1.8%.
-
Profit surprise
EBITDA missed by 22 percent. Operating income missed by 23 percent.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
1 target raise, 5 target cuts.
-
Earnings quality
Gross margin down 1.1 points. Positive free cash flow.
Earnings Call Summary
Danaher started 2026 solidly with adjusted earnings per share of $2.06, up 9.5 percent year over year, beating the consensus of $1.95. Revenue came in at $5.951 billion, slightly below the $6.057 billion expected, due mainly to a lighter respiratory season at Cepheid being down roughly 25 percent. However, strong bioprocessing momentum, with consumables up high single digits and equipment orders surging over 30 percent year over year for the first time in nearly two years, offset weakness. Diagnostics and Life Sciences showed pockets of improvement, with Beckman Coulter diagnostics growing mid single digits outside China and newer products like the Xpert GI panel gaining traction.
Guidance Management raised full year adjusted earnings per share to $8.35 to $8.55 from the prior range. Revenue guidance remains 3 percent to 6 percent growth for the full year, with lower respiratory sales of $1.6 billion to $1.7 billion offset by better core growth elsewhere. Second quarter expected to show low single digit core revenue growth with operating margins around 26.5 percent.
Severe negative reset. The report materially damaged the forward outlook and likely forces major downward revisions.
Dividend
Danaher pays an annual dividend yielding 0.69%, with a payout ratio of 25.7%.
Insider Buying and Selling at Danaher Corporation
Recently, there were a couple of notable insider transactions. Rainer M Blair, the Chief Executive Officer, sold 58,255 shares on August 21, 2026, valued at about $12.7 million. Additionally, Director Alan G Spoon sold 1,358 shares on May 1, 2026, for a total of approximately $237,207.
Analysts Set New Price Targets
On October 1, 2026, Guggenheim maintained a Buy rating with a target of $250. RBC Capital followed on October 5, maintaining an Outperform rating with a target of $250. Barclays also maintained an Overweight rating on October 7, raising its target to $255. Morgan Stanley's recent reiteration aligns with this positive sentiment, as the average target price from analysts stands at approximately $244.14, reflecting a consensus recommendation of Strong Buy from 22 analysts.
About Danaher Corporation
Danaher Corporation designs and manufactures a wide range of products and services for professional, medical, research, and industrial applications. The company operates in various segments, including Biotechnology, Life Sciences, and Diagnostics. Its recent rating reaffirmation from Morgan Stanley highlights the confidence analysts have in its growth potential.
Bottom Line
Investors should keep an eye on Danaher's upcoming earnings report on October 21, 2026, as it may provide further insights into the company's performance. The recent analyst ratings suggest a general positive outlook for Danaher, which has seen consistent institutional interest and strong performance metrics.
Related Filing Alerts
Source: Morgan Stanley's rating change on $DHR (Oct 13, 2026). Written by software, not financial advice. How we make alerts